Therapeutic antibodies
AssigneeIsis Innovation Limited
InventorsHermann Waldmann, Mark Raymond Frewin, Lisa Kim Gilliland, Luis Richardo Simoes da Silva Graca
Life of this patent
Estimating the term…
Abstract
A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.
Claims4
A process for treating lymphoma or marrow transplant rejection or organ transplant rejection or an autoimmune disease in a mammal, comprising:
- administering to said mammal a composition comprising (a) an isolated antibody which binds to CD52, said antibody including a light chain, said light chain consisting essentially of amino acid residues 33 through 263 of SEQ ID No:
- 1;
- and (b) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.